Tag: Michael Frank

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

Revive Therapeutics is pleased to provide a corporate update on its pharmaceutical programs for Bucillamine in the treatment of the...

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

Revive Therapeutics is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program.

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

Revive Therapeutics (CSE:RVV) has received positive feedback from the U.S. FDA in response to the company’s pre-IND meeting that was...

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison

Revive Therapeutics (CSE:RVV) has entered into a SRPA with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery...

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

Revive Therapeutics (CSE:RVV) has engaged Complete Phytochemical Solutions to advance the Company’s research and development initiatives of psilocybin-based products for...

Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

Revive Therapeutics (CSE:RVV) has issued an additional 16,400,000 units at a price of $0.05 per Unit for gross proceeds of...

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

Revive Therapeutics (CSE:RVV)is pleased to announce that the Company has retained Novotech to serve as the Company’s clinical research organization